Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2010
09/02/2010US20100221358 Synthetic derivatives beta glycolipids and compositions thereof for the treatment of pathologic disorders
09/02/2010US20100221357 Drug delivery product and methods
09/02/2010US20100221347 Enhancing solute transport within a tissue scaffold
09/02/2010US20100221339 Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts
09/02/2010US20100221338 Coated Tablets Of 6-(5-Chloro-2-Pyridyl)-5-[(4-Methyl-1-Piperazinyl)Carbonyloxy]-7-Oxo-6,7-Dihydro-5H-Pyrrolo[3,4-b]Pyrazine And Methods For Measuring Effectiveness Of Coating
09/02/2010US20100221331 Pharmaceutical compositions comprising colloidal silicon dioxide
09/02/2010US20100221330 Buoyant formulations of betaine
09/02/2010US20100221328 Sustained-release formulations
09/02/2010US20100221322 Abuse-Resistant Pharmaceutical Dosage Form
09/02/2010US20100221321 Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
09/02/2010US20100221317 Dynamin mediated diseases and associated methods and products
09/02/2010US20100221305 Formulations for coated microprojections containing non-volatile counterions
09/02/2010US20100221298 Novel galenical system for active transport, method for preparation and use
09/02/2010US20100221293 Controlled release formulations of opioid and nonopioid analgesics
09/02/2010US20100221291 Collagen tubes
09/02/2010US20100221259 Nitrogen-containing heterocyclic compounds and medicinal use thereof
09/02/2010US20100221258 Method of treating a pathological syndrome and a pharmaceutical agent
09/02/2010US20100221257 Binding members-513
09/02/2010US20100221244 Antagonizing signal transduction in dorsal root ganglion cells in a subject with il-31 antagonists
09/02/2010US20100221239 Method For Prevention And Treatment Of Alzheimer's Disease
09/02/2010US20100221233 Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
09/02/2010US20100221222 Interferons, uses and compositions related thereto
09/02/2010US20100221187 Treatment of amyloidogenic diseases
09/02/2010US20100221179 IL-1 Binding Proteins
09/02/2010CA2753604A1 Drug combinations containing pde4-inhibitors and nsaids
09/02/2010CA2753597A1 Drug combinations containing pde4-inhibitors and nsaids
09/02/2010CA2753304A1 Tricyclic pyrazolopyrimidine derivatives as hsp inhibitors
09/02/2010CA2752003A1 Ceramide-analogous metabolites
09/02/2010CA2751343A1 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
09/02/2010CA2751322A1 Treatment of dyskinesia related disorders
09/02/2010CA2751321A1 Methods of administering (4ar, 1oar)-1-n-propyl-1,2,3,4a,5,10,10a-octahydrobenzo [g] quinoline-6,7-diol and related compounds across the oral mucosa, the nasal mucosa or the skin and pharmaceutical compositions thereof
09/02/2010CA2751299A1 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
09/02/2010CA2751296A1 Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
09/02/2010CA2751279A1 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, pharmaceutical and cosmetic compositions containing them
09/02/2010CA2749702A1 Salt of tetrahydrotriazolopyridine derivative and crystal thereof
09/02/2010CA2749212A1 Isoxazole / o-pyridine derivatives with ethyl and ethenyl linker
09/01/2010EP2224002A1 Np1 activity regulating elements which can be used in the production of drugs for the treatment or prevention of human neurodegenerative diseases, resulting drugs and use thereof
09/01/2010EP2224000A1 Antibody and use thereof
09/01/2010EP2223922A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta
09/01/2010EP2223920A2 Substituted azabicyclic compounds
09/01/2010EP2223916A1 Morpholine derivatives as norepinephrine reuptake inhibitors
09/01/2010EP2223914A1 Tricyclic condensed pyrazole derivatives as CB1 inhibitors
09/01/2010EP2223703A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient
09/01/2010EP2223689A1 Plastic container having cyclic polyolefin layer
09/01/2010EP2223688A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
09/01/2010EP2223687A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
09/01/2010EP2222702A1 Human monoclonal nicotine specific antibodies
09/01/2010EP2222689A1 Compounds for therapy and diagnosis
09/01/2010EP2222664A1 Cycloalkyloxy-and het rocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor
09/01/2010EP2222650A1 Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor
09/01/2010EP2222632A1 Compounds which potentiate the ampa receptor and uses thereof in medicine
09/01/2010EP2222308A1 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
09/01/2010EP2222304A2 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
09/01/2010EP2222303A1 A method for treating addiction
09/01/2010EP2222300A1 Method and composition for treating a serotonin receptor-mediated condition
09/01/2010EP2222290A1 Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
09/01/2010EP2222287A2 Multitarget compounds active at a ppar and cannabinoid receptor
09/01/2010EP1998778B1 Use of (s)-roscovitine for the prevention and/or treatment of neurological disorders
09/01/2010EP1979322B1 Cyclohexyl sulfonamide derivatives having h3 receptor activity
09/01/2010EP1963337B1 THIENO[2,3-b]PYRIDINE DERIVATIVES
09/01/2010EP1845092B1 Pyrimidinone compounds, their preparation and use thereof
09/01/2010EP1814857B1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
09/01/2010EP1812439B1 Kinase inhibitors
09/01/2010EP1635839B1 Benzo[4,5]thieno[2,3-d]pyrimidin-4-ones and their use in therapy
09/01/2010EP1613347B1 Humanized antibodies that recognize beta amyloid peptide
09/01/2010EP1607394B1 Water-soluble thalidomine derivatives
09/01/2010EP1583525B1 Use of porphyrin synthesis substances in combination with salicylates and antioxidants for use in phototherapy to cure skin and articulation diseases
09/01/2010EP1430027B1 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
09/01/2010EP1423406B1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/01/2010EP1379508B1 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
09/01/2010EP1337558B1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor
09/01/2010CN201564118U Pillow for placing auxiliary substance
09/01/2010CN1976906B Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors
09/01/2010CN1948298B Dopamine D3 acceptor portion agonist and its application
09/01/2010CN1939918B Production of midanping
09/01/2010CN1938018B Use of compounds for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced igf-1 serum level
09/01/2010CN1857345B Hemicrania treating medicine composition and its preparing method
09/01/2010CN1846721B Tranquilizing seven-leaf oral cavity disintegrated tablet and its preparation method
09/01/2010CN1706841B 1-(4,4-diaryl-3-butene)-piperidine formic acid or its medicine salt, preparation process and application
09/01/2010CN101821257A 5-HT7 receptor antagonists
09/01/2010CN101821246A Tetrazole-substituted aryl amide derivatives and uses thereof
09/01/2010CN101821241A Gamma secretase modulators
09/01/2010CN101820911A Humanized antibodies to amyloid beta
09/01/2010CN101820897A Cytoplasmic malate dehydrogenase (MDH1) targeted treatment for neurodegenerative diseases
09/01/2010CN101820896A IGF for the treatment of rett syndrome and synaptic disorders
09/01/2010CN101820884A Phenothiazine compounds for treating mild cognitive impairment
09/01/2010CN101820878A Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
09/01/2010CN101818150A Neurogenesis
09/01/2010CN101817861A Method for preparing high-purity astragaloside for treating diabetes nephropathy and peripheral neuritis of diabetes complications
09/01/2010CN101817852A Preparation of composition containing primaverin and phenethyl ketoside components
09/01/2010CN101817819A 5-alkoxy-tetrazo[1,5-a]qualone derivative and pharmaceutically acceptable salt thereof serving as antidepressants
09/01/2010CN101817808A Flavones derivative as well as preparation method and application thereof as alpha1 receptor antagonist
09/01/2010CN101816771A Chinese medicinal composition for treating epilepsy disease and preparation method thereof
09/01/2010CN101816768A Chinese medicinal composition for treating somatoform disorder and preparation method thereof
09/01/2010CN101816766A Chinese medicinal composition for treating tristimania
09/01/2010CN101816765A Toxin-expelling and skin-nourishing pill
09/01/2010CN101816756A Chinese medicinal composition for treating upset and irritability and preparation method thereof
09/01/2010CN101816751A Medicament for treating epilepsy and tourette syndrome and preparation method thereof
09/01/2010CN101816750A Medicament for treating prosopoplegia
09/01/2010CN101816747A Medicinal preparation for preventing and treating mental diseases such as insomnia and the like and preparation method thereof
1 ... 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 ... 1833